검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | NK cells/Combined Monoclonal Antibodies (NK cells/Combined Monoclonal Antibodies) Artiva Biotherapeutics, Inc.·Hematological Malignancies ORR 25% |
|---|---|
Overview Program | NK cells/Combined Monoclonal Antibodies |
Overview Company | Artiva Biotherapeutics, Inc. |
Overview Modality | CGT |
Overview Target | Hematological Malignancies |
Overview Indication | Hematological Malignancies |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | targeting via chimeric antigen receptor (CAR) against a novel ES target interleukin-1 receptor |
MoA Biomarker | CD19 achieved high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | thrombocytopenia and one of Grade 2 cytokine release syndrome, while Cohort B had one case of &# |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 25% |
Clinical ORR | 25.0% |
Clinical PFS | NA |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT01714739 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | NK cells/Combined Monoclonal Antibodies (NK cells/Combined Monoclonal Antibodies) Artiva Biotherapeutics, Inc.·Hematological Malignancies ORR 25% |
|---|---|
Overview Program | NK cells/Combined Monoclonal Antibodies |
Overview Company | Artiva Biotherapeutics, Inc. |
Overview Modality | CGT |
Overview Target | Hematological Malignancies |
Overview Indication | Hematological Malignancies |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | targeting via chimeric antigen receptor (CAR) against a novel ES target interleukin-1 receptor |
MoA Biomarker | CD19 achieved high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | thrombocytopenia and one of Grade 2 cytokine release syndrome, while Cohort B had one case of &# |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 25% |
Clinical ORR | 25.0% |
Clinical PFS | NA |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT01714739 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교